Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jiangsu Xiansheng Pharmaceutical
Jiangsu, China
- Ownership
- Private
- Development stage
- Other
01
Overview
The company is a subsidiary of Simcere, focused on innovative biologics and small molecules with a pipeline spanning early phase to registration. Lead asset (sevacizumab/ENZESHU) is at NDA/BLA stage for recurrent ovarian and fallopian tube cancer; SIM1811-03 (anti-TNFR2 mAb) in Phase 1 for solid tumors[1][3]. Parent Simcere has multiple approved and late-stage assets[2][5].
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyMulti-specific monoclonal antibodyFusion proteinAntibody-drug conjugateSmall molecule
- Industry
- Biotech
02
Partnerships
Pyxis Oncology (co-development, ENZESHU/suvisexumab)[5]
Beyond the preview
Go deeper on Jiangsu Xiansheng Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jiangsu Xiansheng Pharmaceutical.